The two pharmas are developing an adjuvanted recombinant protein vaccine. Their phase II study, which will enroll 720 adult volunteers, will evaluate three different antigen doses to determine the best strategy for phase III development. If successful, the partners plan to move the candidate into phase III in the second quarter.

Sanofi, GSK COVID-19 vaccine program delayed by responses in elderly
Sanofi and GlaxoSmithKline (GSK) are delaying their adjuvanted recombinant protein-based COVID-19 vaccine program to improve the vaccine's immune response...

If successful, COVID-19 vaccines could be worth $27B
Vaccines are considered one of the most effective public health measures preventing diseases in the modern world. They could also be very profitable endeavors,...

Biopharma CEOs pledge commitment to safe vaccines
The CEOs from nine biopharmaceutical companies have pledged to remain committed to upholding the integrity of the scientific process as they work toward...